Skip to main content
. 2022 Jan 31;28(9):857–872. doi: 10.3727/096504021X16203818567367

Figure 3.

Figure 3

c-Src-mediated caspase 8 phosphorylation inhibited cell death of lung adenocarcinoma through the paclitaxel-triggered necroptosis during EMT. (A, B) A549 cells with control/c-Src/caspase 8 shRNA were treated with cisplatin (50/100/200 μM) (A) or paclitaxel (100/200/300 nM) (B) for 24, 48, and 72 h. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates. *p < 0.05. **p < 0.01. (C) A549 cells with control/c-Src/caspase 8 shRNA was treated with cisplatin (100 μM, upper) or paclitaxel (200 nM, lower) with the addition of dimethyl sulfoxide (DMSO) (control), z-IETD-fmk (50 mM), z-VAD-fmk (50 mM), necrostatin-1 (nec-1) (10 mM), or 3-MA (25 mM) for 48 h. Cell viability was determined by measuring ATP levels using Cell Titer-Glo kit. Data were represented as mean ± standard deviation of duplicates. *p < 0.05. **p < 0.01.